Literature DB >> 26466011

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer.

.   

Abstract

Entities:  

Year:  2015        PMID： 26466011     DOI： 10.1056/NEJMx150034

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

2.  Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocation.

Authors:  Eun Hye Park; Hwa Young Lee; Jin Woo Kim; Chang Dong Yeo
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

3.  Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.

Authors:  Dolores Isla; Bartomeu Massuti; Martín Lázaro; Lucía Ruiz de Alda; Rocio Gordo; Nuria Ortega-Joaquín; Itziar Oyagüez
Journal:  Lung Cancer Manag       Date:  2020-03-04

Review 4.  Development of synthetic lethality in cancer: molecular and cellular classification.

Authors:  Shijie Li; Win Topatana; Sarun Juengpanich; Jiasheng Cao; Jiahao Hu; Bin Zhang; Diana Ma; Xiujun Cai; Mingyu Chen
Journal:  Signal Transduct Target Ther       Date:  2020-10-19

5.  Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer.

Authors:  Zhen Wu; Wei Zhao; Zhen Yang; Yue Ming Wang; Yu Dai; Liang-An Chen
Journal:  Cancer Manag Res       Date:  2021-02-25       Impact factor: 3.989

Review 6.  Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications.

Authors:  A Quintanal-Villalonga; Luis Paz-Ares; Irene Ferrer; S Molina-Pinelo
Journal:  Dis Markers       Date:  2016-07-26       Impact factor: 3.434

7.  hsa_circRNA_012515 Is Highly Expressed in NSCLC Patients and Affects Its Prognosis.

Authors:  Yunfeng Fu; Liang Huang; Hao Tang; Rong Huang
Journal:  Cancer Manag Res       Date:  2020-03-12       Impact factor: 3.989

8.  ILT4 in Colorectal Cancer Cells Induces Suppressive T Cell Contexture and Disease Progression.

Authors:  Zijiang Yang; Aiqin Gao; Wenjing Shi; Jingnan Wang; Xianchao Zhang; Zhengyan Xu; Tingting Xu; Yan Zheng; Yuping Sun; Fei Yang
Journal:  Onco Targets Ther       Date:  2021-07-20       Impact factor: 4.147
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.